Our findings therefore suggest that the poor response of these cases to AML therapy in both adults [53] and children [54] might be improved by better treatment allocation, and would plead against the recent provisional classification of RUNX1-mutated AML-M0 with AML [2]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.